59 related articles for article (PubMed ID: 23244713)
1. Designing a type I interferon signaling phagosome.
Blander JM
Immunity; 2012 Dec; 37(6):947-9. PubMed ID: 23244713
[TBL] [Abstract][Full Text] [Related]
2. Phagosome maturation: steady as she goes.
Underhill DM
Immunity; 2005 Oct; 23(4):343-4. PubMed ID: 16226498
[TBL] [Abstract][Full Text] [Related]
3. Phagosome maturation proceeds independently of stimulation of toll-like receptors 2 and 4.
Yates RM; Russell DG
Immunity; 2005 Oct; 23(4):409-17. PubMed ID: 16226506
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus: all roads lead to type I interferons.
Pascual V; Farkas L; Banchereau J
Curr Opin Immunol; 2006 Dec; 18(6):676-82. PubMed ID: 17011763
[TBL] [Abstract][Full Text] [Related]
5. Syndromes and complications of interferon therapy.
Borg FA; Isenberg DA
Curr Opin Rheumatol; 2007 Jan; 19(1):61-6. PubMed ID: 17143098
[TBL] [Abstract][Full Text] [Related]
6. Bridging Toll-like- and B cell-receptor signaling: meet me at the autophagosome.
Monroe JG; Keir ME
Immunity; 2008 Jun; 28(6):729-31. PubMed ID: 18549794
[TBL] [Abstract][Full Text] [Related]
7. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p.
Zhuang H; Kosboth M; Lee P; Rice A; Driscoll DJ; Zori R; Narain S; Lyons R; Satoh M; Sobel E; Reeves WH
Arthritis Rheum; 2006 May; 54(5):1573-9. PubMed ID: 16645992
[TBL] [Abstract][Full Text] [Related]
8. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
York MR; Nagai T; Mangini AJ; Lemaire R; van Seventer JM; Lafyatis R
Arthritis Rheum; 2007 Mar; 56(3):1010-20. PubMed ID: 17328080
[TBL] [Abstract][Full Text] [Related]
9. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.
Barrat FJ; Meeker T; Gregorio J; Chan JH; Uematsu S; Akira S; Chang B; Duramad O; Coffman RL
J Exp Med; 2005 Oct; 202(8):1131-9. PubMed ID: 16230478
[TBL] [Abstract][Full Text] [Related]
10. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
11. Interferon inhibitor in the blood of patients with systemic lupus erythematosus.
Chadha KC; Ambrus JL; Stadler I; Ambrus JL
J Biol Regul Homeost Agents; 1991; 5(1):1-9. PubMed ID: 1715634
[TBL] [Abstract][Full Text] [Related]
12. [Interleukin 10 in disseminated lupus erythematosus].
Emilie D
J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
[TBL] [Abstract][Full Text] [Related]
13. TLR9 as a key receptor for the recognition of DNA.
Kumagai Y; Takeuchi O; Akira S
Adv Drug Deliv Rev; 2008 Apr; 60(7):795-804. PubMed ID: 18262306
[TBL] [Abstract][Full Text] [Related]
14. Interferons and systemic lupus erythematosus.
Bankhurst AD
J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():63-7. PubMed ID: 2441046
[TBL] [Abstract][Full Text] [Related]
15. Pseudoviral immunity - a novel concept for lupus.
Anders HJ
Trends Mol Med; 2009 Dec; 15(12):553-61. PubMed ID: 19896418
[TBL] [Abstract][Full Text] [Related]
16. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
17. Immune interferon in the circulation of patients with autoimmune disease.
Hooks JJ; Moutsopoulos HM; Geis SA; Stahl NI; Decker JL; Notkins AL
N Engl J Med; 1979 Jul; 301(1):5-8. PubMed ID: 449915
[TBL] [Abstract][Full Text] [Related]
18. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus.
Wenzel J; Zahn S; Bieber T; Tüting T
Arch Dermatol Res; 2009 Jan; 301(1):83-6. PubMed ID: 18784932
[TBL] [Abstract][Full Text] [Related]
19. The role of toll-like receptor 2 in survival strategies of Mycobacterium tuberculosis in macrophage phagosomes.
Yoshida A; Inagawa H; Kohchi C; Nishizawa T; Soma G
Anticancer Res; 2009 Mar; 29(3):907-10. PubMed ID: 19414326
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
